On-label and off-label drug use in the treatment of endometriosis

Quaas, Alexander; Weedin, Elizabeth A.; Hansen, Karl R.

doi:10.1016/j.fertnstert.2015.01.006

Cited by 42 publications

(32 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are rare randomized controlled trials which proved the effects of oral contraceptive for endometriosis-associated pain. In addition, it is not verified that a certain oral contraceptive is better than others [ 42 ]. However, most observational studies and guidelines recommend oral contraceptives as first line treatment for endometriosis-associated pain.…”

Section: Medical Treatment Of Endometriosis-associated Painmentioning

confidence: 99%

Clinical evaluation and management of endometriosis: guideline for Korean patients from Korean Society of Endometriosis

et al. 2018

View full text Add to dashboard Cite

Endometriosis is one of the most common diseases in reproductive ages, and it affects patients' quality of life and fertility. However, few Korean guidelines are available for the evaluation and management of endometriosis. Korean Society of Endometriosis reviewed various literatures and trials, and to provide seventy-one evidence-based recommendations. This review presents guidelines for the diagnosis and management of endometriosis with emphasis on: it's role in infertility, treatment of recurrence, asymptomatic women, endometriosis in adolescents and menopausal women, and possible association of endometriosis with cancer.

show abstract

Section: Medical Treatment Of Endometriosis-associated Painmentioning

confidence: 99%

Clinical evaluation and management of endometriosis: guideline for Korean patients from Korean Society of Endometriosis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…3,5 A plethora of pharmaceutical agents are prescribed for management of pain associated with endometriosis, although few of these have been approved for this indication by regulatory bodies. 10 Among commonly used off-label agents are combined hormonal contraceptives. Findings from a recent meta-analysis revealed that, whereas evidence suggests combined hormonal contraceptives reduce endometriosisassociated pain, supportive data are low quality and there are insufficient data comparing these agents with other options for managing endometriosis-associated pain.…”

Section: Introductionmentioning

confidence: 99%

A Clinician's Guide to the Treatment of Endometriosis with Elagolix

Leyland

Estes

Lessey³

et al. 2021

Journal of Women's Health

View full text Add to dashboard Cite

Pain associated with endometriosis is a considerable burden for women, permeating all aspects of their lives, from their ability to perform daily activities to their quality of life. Although there are many options for endometriosis-associated pain management, they are often limited by insufficient efficacy, inconvenient routes of administration, and/or intolerable side effects. Elagolix, a nonpeptide, small-molecule gonadotropinreleasing hormone (GnRH) receptor antagonist, is the first new oral therapy to be approved for the treatment of endometriosis-associated pain in the United States in more than a decade. Modulation of estradiol with elagolix is dose dependent and ranges from partial to full suppression. Clinical evidence has shown that elagolix at both approved doses (150 mg once daily and 200 mg twice daily) is effective for reducing symptoms of pelvic pain (dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia), improving quality of life, and decreasing use of rescue analgesics (nonsteroidal anti-inflammatory drugs and/or opioids). The availability of two dosing options allows for individualization of treatment based on baseline clinical factors and response to therapy. Elagolix is well tolerated, with less pronounced hypoestrogenic effects compared with GnRH agonists. This review provides an overview of elagolix, highlighting currently available treatment options and the application of this new treatment for women with endometriosis-associated pain.

show abstract

“…Common therapies against EM aim at reducing pain and infertility issues. 2,[9][10][11] Besides surgical resection of the lesions, primary treatments consist of administration of drugs targeting hormone control and/or inflammation. Growth of endometrial cells in ectopic locations still responds to, and depends on, estradiol stimulation.…”

Section: Hormonal Control Of the Menstrual Cycle And Of Endometriosismentioning

confidence: 99%

Are matrix metalloproteinases and their inhibitors reliable diagnosis biomarkers and attractive therapeutic targets in endometriosis?

Henriet¹,

Mon²,

Marbaix³

2016

MNM

View full text Add to dashboard Cite

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are expressed in the human endometrium during the menstrual cycle, in particular to induce substantial extracellular matrix breakdown underlying menstruation. Endometriosis (EM) is characterized by the presence of endometrial tissue at ectopic locations. Because EM is thought to often develop from retrograde menstruation followed by implantation of menstrual tissue fragments at ectopic sites, endometrial MMPs and TIMPs were rapidly suspected as contributors to EM development and progression, generating hope for their use as biomarkers to facilitate EM diagnosis and as potential targets for developing new therapies against EM. Here, we not only summarize a substantial literature supporting the presence of MMPs and TIMPs in eutopic and ectopic endometrium of EM patients but also highlight frequent controversies on expression changes and the difficulty in identifying systematic MMP/TIMP differential regulation associated with the disease. Moreover, by reanalyzing publicly available data from a whole genome transcriptomic study, we show that occasional and unexplained endometrial overexpression of selective MMPs regardless of the disease and phase of the menstrual cycle rather discourages the use of eutopic MMPs and TIMPs as diagnosis biomarkers. However, we also review multiple studies using rodent models that collectively provide strong support to the contribution of MMPs in EM development and progression, and therefore to further investigations aiming at targeting MMP activity, especially in light of recent advances in new MMP inhibitors.

show abstract

On-label and off-label drug use in the treatment of endometriosis

Cited by 42 publications

References 83 publications

Clinical evaluation and management of endometriosis: guideline for Korean patients from Korean Society of Endometriosis

Clinical evaluation and management of endometriosis: guideline for Korean patients from Korean Society of Endometriosis

A Clinician's Guide to the Treatment of Endometriosis with Elagolix

Are matrix metalloproteinases and their inhibitors reliable diagnosis biomarkers and attractive therapeutic targets in endometriosis?

Contact Info

Product

Resources

About